Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bluebird Bio (BLUE)

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,741,314
  • Shares Outstanding, K 55,331
  • Annual Sales, $ 54,580 K
  • Annual Income, $ -555,630 K
  • 60-Month Beta 2.16
  • Price/Sales 77.66
  • Price/Cash Flow N/A
  • Price/Book 2.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -3.79
  • Number of Estimates 12
  • High Estimate -3.02
  • Low Estimate -4.11
  • Prior Year -2.72
  • Growth Rate Est. (year over year) -39.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.42 +19.98%
on 11/22/19
86.09 -0.46%
on 12/10/19
+7.72 (+9.90%)
since 11/08/19
3-Month
71.42 +19.98%
on 11/22/19
109.58 -21.80%
on 09/20/19
-16.10 (-15.82%)
since 09/10/19
52-Week
71.42 +19.98%
on 11/22/19
163.43 -47.57%
on 04/03/19
-16.46 (-16.11%)
since 12/10/18

Most Recent Stories

More News
Fate (FATE) Announces Encouraging Data on Immunotherapies

Fate (FATE) gains on positive data from cellular immunotherapies and preclinical study data.

BMY : 62.09 (+1.32%)
GILD : 67.08 (+0.22%)
FATE : 18.91 (-2.12%)
BLUE : 85.69 (+11.87%)
bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

--CAR T persistence observed in 8/10 evaluable responders at Month 6 and 2/2 evaluable responders at Month 18

BLUE : 85.69 (+11.87%)
BMY : 62.09 (+1.32%)
bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin(TM) Gene Therapy for B-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

--Ninety percent of evaluable patients who do not have a B(0)/B(0 )genotype achieved TI, with median average total Hb levels of 12.2 g/dL in Phase 3 Northstar-2 (HGB-207) study

BLUE : 85.69 (+11.87%)
bluebird Reports Positive Top-Line Data on Myeloma Drug

bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.

BMY : 62.09 (+1.32%)
BLUE : 85.69 (+11.87%)
ANIK : 55.42 (-0.22%)
ALKS : 21.57 (-0.78%)
Look for Shares of Bluebird Bio Inc to Potentially Rebound after Yesterday's 2.69% Sell Off

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $75.11 to a high of $83.92. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of...

BLUE : 85.69 (+11.87%)
bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin(TM) Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition

--Group C patients at six months post-treatment produced consistent median levels of gene therapy-derived anti-sickling hemoglobin (HbAT87Q) ranging from 44 - 59% (Month 6 - 21), reducing the median level...

BLUE : 85.69 (+11.87%)
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma

--Safety results are consistent with the data presented in CRB-401 study

BMY : 62.09 (+1.32%)
BLUE : 85.69 (+11.87%)
Stocks Rebound and Hang Onto Recent Gains

Stocks Rebound and Hang Onto Recent Gains

ORI : 22.77 (+0.09%)
AOBC : 9.08 (+1.68%)
RLGY : 10.55 (-1.49%)
BLUE : 85.69 (+11.87%)
TRHC : 39.84 (-1.34%)
NVTA : 17.72 (+3.69%)
Look for Shares of Bluebird Bio Inc to Potentially Pullback after Yesterday's 1.83% Rise

Bluebird Bio Inc (NASDAQ:BLUE) traded in a range yesterday that spanned from a low of $80.20 to a high of $85.33. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high...

BLUE : 85.69 (+11.87%)
Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?

Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.

BLUE : 85.69 (+11.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BLUE with:

Business Summary

Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio,...

See More

Key Turning Points

2nd Resistance Point 92.84
1st Resistance Point 89.27
Last Price 85.69
1st Support Level 78.94
2nd Support Level 72.18

See More

52-Week High 163.43
Fibonacci 61.8% 128.28
Fibonacci 50% 117.42
Fibonacci 38.2% 106.57
Last Price 85.69
52-Week Low 71.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar